近五年来，爱博医疗研发团队规模扩大近三倍，在产品布局上不断推陈出新，并在创新医疗器械审评审批等 国家政策的精准扶持下，成功推动三款自研产品通过特别审查程序获批，将针对创新产品的政策红利转化为服务 患者的先进成果。 超越对创新速度的追求，爱博医疗更专注于提升自研创新的"含金量"与可持续性，不断巩固并拓展在超精密 加工、医用高分子材料等五大核心技术的平台优势。截至2024年底，爱博医疗累计获得授权且有效专利256项，其 中近五年内获授权占比超过半数。2022年，爱博医疗推出中国首款全程视力多焦点人工晶状体普诺明®全视； 2025年，推出全国首款非球面有晶体眼人工晶状体龙晶®PR，有望再次打破海外厂商的长期垄断。 中国上市公司协会联合新华网等媒体，开展"我在'十四五'这五年 上市公司在行动"主题宣传活动。眼睛是我 们感知世界的重要窗口，良好的视觉质量是保障生活品质的重要基石。秉持"科技点亮视界"的愿景，中国眼科领 域的领先企业爱博医疗，致力于为眼科手术、屈光矫正及视光消费提供全方位的一站式解决方案，产品覆盖眼科 手术治疗、近视防控与视力保健三大领域。2020年，爱博医疗成功登陆上海证券交易所科创板，由此迈入规模化 ...

Core Viewpoint - The article highlights the recent approval of four innovative medical devices by the National Medical Products Administration in China, indicating a growing trend in the development and registration of innovative medical technologies in the country [1][8]. Group 1: Approved Products - The approved products include: 1. "Extended Depth of Focus Intraocular Lens" by Aibono Medical Technology Co., Ltd. [1] 2. "Cardiac Cryoablation Device" and "Single-use Sterile Cryoablation Probe" by Shenyang Pengyue Technology Co., Ltd. [1][8] 3. "Cross-linked Polyisobutylene Aspheric Intraocular Lens" by Xi'an Yandale Medical Technology Co., Ltd. [1][8] - As of now, a total of 373 innovative medical devices have been registered in China [1]. Group 2: Company Profiles - Aibono Medical Technology Co., Ltd. is an innovative ophthalmic medical device manufacturer listed on the Sci-Tech Innovation Board, focusing on cataract surgery, myopia control, and vision care solutions. The company reported a total revenue of 787 million yuan (approximately $114 million) with a year-on-year growth of 14.72% and a net profit of 213 million yuan (approximately $31 million) with a growth of 2.53% in the first half of 2025 [6]. - Shenyang Pengyue Technology Co., Ltd., established in 2020, specializes in digital intelligent precision medical fields and has developed a cardiac cryoablation system with independent intellectual property rights [10]. - Xi'an Yandale Medical Technology Co., Ltd. focuses on intraocular lenses for cataract treatment and is led by a team of experts, including members from the American Academy of Engineering [18]. Group 3: Product Details - The "Extended Depth of Focus Intraocular Lens" is designed for vision correction after cataract surgery, featuring a one-piece, foldable design made from a combination of ethyl acrylate and methyl methacrylate [5]. - The "Cardiac Cryoablation Device" is used for treating persistent atrial fibrillation in adult patients, utilizing argon gas for rapid cooling of myocardial cells [9]. - The "Cross-linked Polyisobutylene Aspheric Intraocular Lens" is notable for its high refractive index and is designed for implantation through a small incision, providing an improved visual experience for cataract patients [15].

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the past 30 days include Mindray Medical, Huichuan Technology, United Imaging Healthcare, Shenzhen South Circuit, and Aibo Medical [11][13] - In the last five days, the most popular companies for institutional research include Jepu Tech, Ganli Pharmaceutical, Shiji Information, Guangri Co., and Nenghui Technology [11][12] - Among the top twenty companies in the past 30 days, 12 companies had 10 or more rating agencies involved, with significant profit growth expected for Lankai Technology, Huichuan Technology, and Sanhua Intelligent Control in their 2025 mid-year reports compared to 2024 [11][12] Group 2: Shareholder Increase and Buyback Strategies - From September 22 to September 26, 2025, four listed companies announced significant shareholder increases [18] - A total of 71 companies announced buyback progress during the same period, with 22 of them having 10 or more rating agencies involved [24] - From January 1 to September 26, 2025, 274 companies announced shareholder increases, with 86 of them having 10 or more rating agencies involved [20] Group 3: Buyback Situation - From January 1 to September 26, 2025, 1,747 companies announced buyback progress, with 414 of them having 10 or more rating agencies involved [26] - Among these, 108 companies had a buyback amount that exceeded 1% of their market value on the announcement date [26][27] - Specific companies in the buyback phase include Chengde Lulu, Liugong, Shantui, Huaming Equipment, Jian Sheng Group, Ruoyu Chen, and China Jushi [27]

Core Insights - The main point of the news is the net inflow of capital in the Shanghai and Shenzhen stock markets, amounting to 9.527 billion yuan, with a notable outflow in the Sci-Tech Innovation Board [1] Group 1: Market Overview - The total net inflow of capital in the Shanghai and Shenzhen markets was 9.527 billion yuan, with the Sci-Tech Innovation Board experiencing a net outflow of 4.624 billion yuan [1] - A total of 210 stocks saw net inflows, while 377 stocks experienced net outflows [1] Group 2: Stock Performance - On the Sci-Tech Innovation Board, 404 stocks increased in value, with three stocks hitting the daily limit up, including Pinming Technology and Fuzhi Environmental Protection [1] - Among the stocks with net inflows, 9 stocks had inflows exceeding 100 million yuan, with Lanqi Technology leading at 302 million yuan [2] - The stocks with the highest net outflows included Haiguang Information, which saw a net outflow of 1.077 billion yuan, followed by Chip Origin and Crystal Integration with outflows of 297 million yuan and 267 million yuan, respectively [1][2] Group 3: Continuous Capital Flow - There were 39 stocks with continuous net inflows for more than three trading days, with Hanwujing leading at 29 consecutive days [2] - A total of 166 stocks experienced continuous net outflows, with Aibo Medical leading at 15 consecutive days [2] Group 4: Detailed Stock Data - The top stocks by net inflow included: - Lanqi Technology: 301.69 million yuan, 4.29% inflow rate, 7.93% increase [2] - Zhongwei Company: 271.03 million yuan, 4.45% inflow rate, 5.17% increase [2] - Wealth Trend: 155.91 million yuan, 9.66% inflow rate, 7.51% increase [2] - The stocks with the highest net outflows included: - Haiguang Information: 1.077 billion yuan, 1.26% decrease [1] - Chip Origin: 297 million yuan, 2.67% decrease [1] - Crystal Integration: 267 million yuan, 2.67% decrease [1]

Core Viewpoint - Aibo Medical has received approval from the National Medical Products Administration for its "Extended Focus Artificial Lens" through the special review for innovative medical devices [2] Company Summary - Aibo Medical announced the registration approval of its "Extended Focus Artificial Lens" [2] Industry Summary - The approval signifies a positive development in the medical device sector, particularly in innovative ophthalmic solutions [2]

Core Viewpoint - Aibo Medical has received approval from the National Medical Products Administration for its "Extended Depth of Focus Intraocular Lens," marking a significant advancement in high-end refractive intraocular lenses for cataract surgery [1] Company Summary - Aibo Medical's new product is designed for vision correction in adults who have undergone cataract surgery and have no natural lens [1] - The lens utilizes advanced aspheric design to extend the depth of focus, improving intermediate vision while maintaining distance vision [1] - The product aims to reduce dependency on glasses for patients post-surgery [1]

Core Viewpoint - Aibo Medical has received approval from the National Medical Products Administration for its "Extended Depth of Focus Intraocular Lens," marking a significant advancement in high-end refractive intraocular lenses for vision correction post-cataract surgery [1]. Company Summary - Aibo Medical's new product is designed for adults who have undergone cataract surgery and have no natural lens, aiming to improve intermediate vision while maintaining distance vision [1]. - The lens utilizes advanced aspheric design to enhance depth of focus without significantly compromising distance vision, thereby reducing dependence on glasses [1].

爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）之"焦深延 长型人工晶状体"于近日通过国家药品监督管理局创新医疗器械特别审查获准注 册，现将相关情况公告如下： 一、产品基本信息 产品名称：焦深延长型人工晶状体 型号、规格：型号：AE2UV；AE2UL22（预装式焦深延长型人工晶状体）、 AE2UL24（预装式焦深延长型人工晶状体）、AE2UL28（预装式焦深延长型人工 晶状体）；规格（光焦度）：-10.0～+36.0D，每 0.5D 一个间隔。 适用范围：适用于成年人白内障摘除手术后无晶状体眼的视力矫正，通过扩 展焦深改善中视力以降低对眼镜的依赖程度。 注册类别：Ⅲ类 注册证编号：国械注准 20253161914 证券代码：688050 证券简称：爱博医疗 公告编号：2025-050 爱博诺德（北京）医疗科技股份有限公司 关于焦深延长型人工晶状体通过创新医疗器械特别 审查程序获批上市的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司尚无法预测该医疗器械对公司未来业绩的影响，敬请广大投资者予以关 注 ...

Core Viewpoint - Aibo Medical (688050.SH) has received approval from the National Medical Products Administration for its "Extended Depth of Focus Intraocular Lens," marking a significant advancement in its product offerings [1] Company Summary - The "Extended Depth of Focus Intraocular Lens" is categorized as a high-end refractive intraocular lens, designed for vision correction in adults who have undergone cataract surgery and have no natural lens [1] - The product utilizes advanced aspheric design to extend the depth of focus, improving intermediate vision while maintaining distance vision without significantly reducing it, thereby decreasing reliance on glasses [1]

Core Points - The company Aibo Medical announced that its "Extended Depth of Focus Intraocular Lens" has been approved for registration by the National Medical Products Administration under the special review for innovative medical devices [2] - This product is classified as a high-end refractive intraocular lens, designed for vision correction in adults who have undergone cataract surgery and have no natural lens [2] - The lens features a high-order aspheric design that enhances intermediate vision while maintaining distance vision, thereby reducing dependence on glasses [2]